Soutenir la recherche

Actualités

Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025)

6 mai 2020

Laurent Softic, Rozenn Brillet, François Berry, Nazim Ahnou, Quentin Nevers, Margot Morin-Dewaele, Sabah Hamadat, Patrice Bruscella, Slim Fourati, Jean-Michel Pawlotsky, Abdelhakim Ahmed-Belkacem

ABSTRACT

Cyclophilins play a key role in the lifecycle of coronaviruses. Alisporivir (Debio 025) is a non-immunosuppressive analogue of cyclosporin A with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in VeroE6 cell line, with an EC50 of 0.46±0.04 μM. Alisporivir inhibited a post-entry step of the SARS-CoV-2 lifecycle. These results justify that a proof-of-concept Phase 2 trial be rapidly conducted with alisporivir in patients with SARS-CoV-2 infection.Copyright © 2020 American Society for Microbiology.

Consultez l'article  https://aac.asm.org/content/early/2020/05/05/AAC.00876-20

Toutes les actualités Suivant